Our Approach

We serve as senior management in our investments, driving business and product development strategy. Our team brings extensive, complementary experience both as investors and senior operating executives at biotechnology companies, with responsibilities that spanned discovery, pre-clinical and clinical development, business development, finance and executive management. We have worked together in both investment and corporate environments over the course of more than 15 years.

We are building on HealthCare Ventures’ 30 years of experience in investing in the life sciences. Since its founding in 1985, HealthCare Ventures has raised $1.6 billion in nine funds. We have invested in 107 companies, 68 as startup ventures. We have had many notable successes in developing innovative pharmaceuticals such as CAMPATH®, Synagis®, Velcade®, and Zolinza®, and in achieving high-value exits, including Aton (acquired by Merck), Avidia (acquired by Amgen), Dendreon, Human Genome Sciences (founding and sale of Principia); LeukoSite (acquired by Millennium), MedImmune (acquired by AstraZeneca), Novazyme (acquired by Genzyme), Shire (direct investment and sale of Pharmavene), Vicuron (acquired by Pfizer), FoldRx (acquired by Pfizer), and Arresto (acquired by Gilead).

Investment Team

Augustine Lawlor

Gus Lawlor has been a managing director of HealthCare Ventures since 2000. He was previously chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company. Before joining LeukoSite, he was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. He was previously a management consultant with KPMG Peat Marwick. He is a member of the Yale SOM Entrepreneurship Advisory Board. He received a Master’s degree in Public and Private Management from Yale University.

Christopher K. Mirabelli, Ph.D.

Chris Mirabelli joined HealthCare Ventures as a managing director in 2000. Dr. Mirabelli was chairman of the board and chief executive officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. He was a co-founder of Isis Pharmaceuticals. He was previously with SmithKline and French Laboratories R&D Division. He is a member of the board of advisors of the Accelerator Fund at Harvard Medical School. He received his Doctor of Philosophy degree in molecular pharmacology from Baylor College of Medicine in Houston, Texas.

Douglas E. Onsi

Doug Onsi joined HealthCare Ventures in 2007. He was previously at Genzyme Corporation, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology and as Vice President, Business Development. Prior to joining Genzyme, Doug was chief financial officer of Tolerx, Inc., a HealthCare Ventures VI company. Before joining Tolerx, he was in business development at LeukoSite, a HealthCare Ventures III, IV, and V company. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi is a member of the business and scientific advisory board for FastForward, a subsidiary of the National Multiple Sclerosis Society, and on the Cornell University Council. He received a Juris Doctor degree from the University of Michigan Law School and an undergraduate degree in biology from Cornell University.

Senior Advisors and Fund III-VIII Partners

James H. Cavanaugh, Ph.D.

James Cavanaugh has been a managing director of HealthCare Ventures since 1989. He was previously president of SmithKline & French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. He had been president of SmithKline Beckman's clinical laboratory business and President of Allergan International. He served as staff assistant to President Nixon for Health Affairs and then deputy director of the president’s Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House. He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his Master’s and Doctorate degrees.

John W. Littlechild

John Littlechild has been a managing director of HealthCare Ventures since 1992. He has been in the venture capital industry since 1980 when he joined Citicorp Venture Capital in London. He subsequently joined the Advent Group, opening the London office of Advent U.K. and becoming an early general partner of Advent International in Boston. Prior to his career in venture capital, he held marketing and financial management positions with Rand, Xerox and ICI. Mr. Littlechild is a member of the board of fellows of the Council for Harvard Medicine. He received his Master in Business Administration degree from Manchester Business School.

Harold R. Werner

Hal Werner was a co-founder of HealthCare Ventures in 1985. Prior to the formation of HealthCare Ventures, Mr. Werner was director of new ventures for Johnson & Johnson Development Corporation. Before joining Johnson & Johnson, he was senior vice president of Robert S. First, Inc., an international healthcare consulting firm. He received his Master in Business Administration degree from the Harvard Graduate School of Business Administration.